Clinical Research Directory
Browse clinical research sites, groups, and studies.
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Summary
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
Official title: Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
377
Start Date
2023-10-25
Completion Date
2028-08
Last Updated
2024-02-21
Healthy Volunteers
Not specified
Conditions
Locations (1)
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China